News on Lipid Sciences from BioPortfolio.com http://www.BioPortfolio.com Consolidated Lipid Sciences news from BioPortfolio.com Wed, 10 Feb 2010 15:09:27 GMT en Medical Expert Available Regarding FDA Expanding Rosuvastatin Use to People with Normal LDL Cholesterolhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039346&HITNO=0&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039346&THISHREF=http://c.moreover.com/click/here.pl%3fz2538045513%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4039346&HITNO=0&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4039346&THISHREF=http://c.moreover.com/click/here.pl%3fz2538045513%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNewswise: Pacific Biomarkers, Inc. Schedules Second Quarter Conference Call for Friday, February 12, 2010http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038926&HITNO=1&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038926&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838317%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4038926&HITNO=1&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4038926&THISHREF=http://c.moreover.com/click/here.pl%3fz2537838317%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042686&HITNO=2&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042686&THISHREF=http://c.moreover.com/click/here.pl%3fz2539501975%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042686&HITNO=2&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042686&THISHREF=http://c.moreover.com/click/here.pl%3fz2539501975%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comYahoo! Canada: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042557&HITNO=3&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042557&THISHREF=http://c.moreover.com/click/here.pl%3fz2539453567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042557&HITNO=3&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042557&THISHREF=http://c.moreover.com/click/here.pl%3fz2539453567%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042250&HITNO=4&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042250&THISHREF=http://c.moreover.com/click/here.pl%3fz2539365465%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042250&HITNO=4&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042250&THISHREF=http://c.moreover.com/click/here.pl%3fz2539365465%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042238&HITNO=5&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042238&THISHREF=http://c.moreover.com/click/here.pl%3fz2539364306%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042238&HITNO=5&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042238&THISHREF=http://c.moreover.com/click/here.pl%3fz2539364306%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFreshnews.com: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042180&HITNO=6&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042180&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042180&HITNO=6&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042180&THISHREF=http://c.moreover.com/click/here.pl%3fz2539342533%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042169&HITNO=7&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042169&THISHREF=http://c.moreover.com/click/here.pl%3fz2539340197%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042169&HITNO=7&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042169&THISHREF=http://c.moreover.com/click/here.pl%3fz2539340197%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Market Report -- In Play (GENZ)http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042126&HITNO=8&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042126&THISHREF=http://c.moreover.com/click/here.pl%3fz2539320253%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042126&HITNO=8&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042126&THISHREF=http://c.moreover.com/click/here.pl%3fz2539320253%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBriefing.com via MSN Money: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042072&HITNO=9&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042072&THISHREF=http://c.moreover.com/click/here.pl%3fz2539300606%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042072&HITNO=9&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042072&THISHREF=http://c.moreover.com/click/here.pl%3fz2539300606%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042034&HITNO=10&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042034&THISHREF=http://c.moreover.com/click/here.pl%3fz2539288477%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4042034&HITNO=10&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4042034&THISHREF=http://c.moreover.com/click/here.pl%3fz2539288477%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meetshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041919&HITNO=11&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041919&THISHREF=http://c.moreover.com/click/here.pl%3fz2539255920%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041919&HITNO=11&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041919&THISHREF=http://c.moreover.com/click/here.pl%3fz2539255920%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comForbes.com: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041846&HITNO=12&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041846&THISHREF=http://c.moreover.com/click/here.pl%3fz2539239600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041846&HITNO=12&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041846&THISHREF=http://c.moreover.com/click/here.pl%3fz2539239600%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comEarthtimes.org: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041749&HITNO=13&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041749&THISHREF=http://c.moreover.com/click/here.pl%3fz2539219766%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041749&HITNO=13&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041749&THISHREF=http://c.moreover.com/click/here.pl%3fz2539219766%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire via Yahoo!: Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041738&HITNO=14&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041738&THISHREF=http://c.moreover.com/click/here.pl%3fz2539217696%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4041738&HITNO=14&MSIZE=695&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Lipid%20Sciences&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4041738&THISHREF=http://c.moreover.com/click/here.pl%3fz2539217696%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinanzNachrichten.de: